Abstract
BackgroundVerinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for the treatment of gout and asymptomatic hyperuricemia.ObjectivesThis Phase 1, single-dose, open-label study investigated the pharmacodynamics (PD), pharmacokinetics (PK), and...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
